Loading...
•
Jun 30, 2025
Intellia Q2 2025 Earnings Report
Intellia Therapeutics announced its second quarter 2025 financial results, highlighting progress in its clinical programs and financial position.
Key Takeaways
Intellia Therapeutics reported a significant reduction in net loss for Q2 2025, decreasing to $101.3 million from $147.0 million in Q2 2024. Collaboration revenue increased, and operating expenses saw a notable decrease, primarily driven by lower R&D and G&A expenses. The company ended the quarter with a strong cash position, expected to fund operations into the first half of 2027.
Net loss significantly decreased to $101.3 million in Q2 2025 from $147.0 million in Q2 2024.
Collaboration revenue increased by 104.7% to $14.2 million in Q2 2025, primarily due to cost reimbursements from the Regeneron collaboration.
Total operating expenses decreased by 15% to $124.2 million, driven by reductions in R&D and G&A expenses.
Cash, cash equivalents, and marketable securities stood at $630.5 million, providing a runway into the first half of 2027 and anticipated first commercial launch.
Revenue by Segment
Forward Guidance
Intellia Therapeutics provided positive updates on its clinical trials, with enrollment tracking ahead of projections for key programs and an expanded patient number for the MAGNITUDE study. The company expects to complete randomization in the HAELO study in Q3 2025 and complete enrollment in the MAGNITUDE-2 study in H1 2026. Financial runway is projected into the first half of 2027.
Positive Outlook
- Enrollment in the global Phase 3 MAGNITUDE trial for ATTR-CM is ahead of projections, tracking to enroll at least 650 patients cumulatively by year-end.
- Total enrollment of the MAGNITUDE study is expanding to approximately 1,200 patients, providing a more robust dataset without impacting projected timelines or financial runway.
- Enrollment in the global Phase 3 MAGNITUDE-2 study for ATTRv-PN is ahead of schedule, with completion expected in the first half of 2026.
- Randomization in the global Phase 3 HAELO study for HAE is expected to be completed during the third quarter of 2025, ahead of original plans.
- The company's cash, cash equivalents, and marketable securities are expected to fund operations into the first half of 2027 and into the anticipated first commercial launch.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...